Escalating Prevalence of Hormone-Sensitive Malignancies
Breast cancer has emerged as the most common cancer among women across Brazil, Russia, India, and China, with hormone receptor–positive (HR+) subtypes representing a significant share of cases. In men, prostate cancer incidence is increasing, particularly in Russia and Brazil, as life expectancy rises and screening becomes more common. These trends create a growing demand for endocrine therapies across early-stage, adjuvant, and advanced disease settings.
In Brazil and China, expanding urban oncology centers provide broad access to guideline-based care, while rural areas may face delayed diagnoses and limited therapy options. Russia’s well-established oncology network ensures the availability of standard endocrine treatments, but late-stage presentations remain frequent in remote regions. India’s public and private healthcare mix results in variable access, with metropolitan centers offering advanced hormone therapy regimens while smaller hospitals rely on conventional agents.
Beyond breast and prostate cancer, other hormone-sensitive malignancies—including select endometrial and ovarian cancers— contribute to the treatment burden. Improvements in pathology services and hormone receptor testing are gradually enhancing the identification of eligible patients, allowing clinicians to optimize therapy selection and monitor for resistance.
Rising Utilization of Combination-Based Regimens
Combination hormone therapy regimens are integrated into cancer care in the BRICS nations, particularly for advanced or high-risk disease. In HR+ breast cancer, physicians combine aromatase inhibitors or selective estrogen receptor modulators with ovarian suppression or other systemic agents to extend progression-free survival. Such approaches are becoming standard in urban oncology centers in Brazil, China, and Russia, where multidisciplinary teams support evidence-based decision-making.
Prostate cancer management is evolving, with androgen deprivation therapy frequently paired with novel anti-androgens or chemohormonal strategies for metastatic or high-risk patients. In China and Russia, these combinations are supported by national treatment guidelines. In India and Brazil, the adoption is increasing in private and academic hospitals, highlighting growing alignment with international clinical standards.
The expansion of combination regimens is facilitated by increasing access to diagnostic services, pathology, and tumor boards, which help personalize therapy according to disease stage, biomarker status, and patient factors. Regional collaborations and educational initiatives are supporting the standardization of hormone therapy protocols, enabling clinicians to optimize treatment efficacy and reduce adverse effects. Combination hormone therapy is becoming a central feature of modern cancer management across the region.
